Skip to main content

Advertisement

Innovative Therapies

Section information

Section Editor : David Segal

Epigenome-wide association studies result in lists of disease-associated epigenetic abnormalities. To exploit such mutations beyond their use as biomarkers, innovative epigenetic therapies (including but not limited to epigenetic editing) are expected to be further developed into the preclinical and clinical testing phase. This section publishes research and reviews on the development of epigenetic rewriting agents for the treatment of diseases, which do not belong to the conventional class of chemical epigenetic enzyme inhibitors.

  1. Nearly 25% of long intergenic non-coding RNAs (lincRNAs) recruit chromatin-modifying proteins (e.g., EZH2) to silence target genes. HOX antisense intergenic RNA (HOTAIR) is deregulated in diverse cancers and c...

    Authors: Yu Ren, Yun-fei Wang, Jing Zhang, Qi-xue Wang, Lei Han, Mei Mei and Chun-sheng Kang

    Citation: Clinical Epigenetics 2019 11:29

    Content type: Research

    Published on:

  2. The diagnosis of glioblastoma (GBM), a most aggressive primary brain tumor with a median survival of 14.6 months, carries a dismal prognosis. GBMs are characterized by numerous genetic and epigenetic alteratio...

    Authors: Halina Was, Sylwia K. Krol, Dante Rotili, Antonello Mai, Bartosz Wojtas, Bozena Kaminska and Marta Maleszewska

    Citation: Clinical Epigenetics 2019 11:11

    Content type: Research

    Published on:

  3. In osteosarcoma (OS), chemotherapy resistance has become one of the greatest issues leading to high mortality among patients. However, the mechanisms of drug resistance remain elusive, limiting therapeutic eff...

    Authors: Chao He, Jian Sun, Chao Liu, Yuhang Jiang and Yongqiang Hao

    Citation: Clinical Epigenetics 2019 11:8

    Content type: Research

    Published on:

  4. There are some limitations of standard chemotherapy for acute leukemia. Vincristine and doxorubicin are commonly used for acute leukemia, but they may induce serious side effects such as cardiomyopathy and neu...

    Authors: Huang-Ju Tu, Yi-Jyun Lin, Min-Wu Chao, Ting-Yi Sung, Yi-Wen Wu, Yi-Ying Chen, Mei-Hsiang Lin, Jing-Ping Liou, Shiow-Lin Pan and Chia-Ron Yang

    Citation: Clinical Epigenetics 2018 10:162

    Content type: Research

    Published on:

  5. Histone deacetylase inhibitors (HDACi) are promising anti-cancer drugs that could also be employed for urothelial carcinoma (UC) therapy. It is unclear, however, whether inhibition of all 11 zinc-dependent HDA...

    Authors: Aline Kaletsch, Maria Pinkerneil, Michèle J. Hoffmann, Ananda A. Jaguva Vasudevan, Chenyin Wang, Finn K. Hansen, Constanze Wiek, Helmut Hanenberg, Christoph Gertzen, Holger Gohlke, Matthias U. Kassack, Thomas Kurz, Wolfgang A. Schulz and Günter Niegisch

    Citation: Clinical Epigenetics 2018 10:100

    Content type: Research

    Published on:

  6. Lack of vitamin D (VD) has been associated with colorectal cancer (CRC). VD has anti-inflammatory effects and regulates several cellular pathways by means of its receptor, including epigenetic modifications. A...

    Authors: Daniel Castellano-Castillo, Sonsoles Morcillo, Mercedes Clemente-Postigo, Ana Belén Crujeiras, Jose Carlos Fernandez-García, Esperanza Torres, Francisco José Tinahones and Manuel Macias-Gonzalez

    Citation: Clinical Epigenetics 2018 10:60

    Content type: Research

    Published on:

  7. New efficient therapies for urothelial carcinoma (UC) are urgently required. Small-molecule drugs targeting chromatin regulators are reasonable candidates because these regulators are frequently mutated or der...

    Authors: Alexander S. Hölscher, Wolfgang A. Schulz, Maria Pinkerneil, Günter Niegisch and Michèle J. Hoffmann

    Citation: Clinical Epigenetics 2018 10:1

    Content type: Research

    Published on:

  8. Hypericin-mediated photodynamic therapy (HY-PDT) has recently captured increased attention as an alternative minimally invasive anticancer treatment, although cancer cells may acquire resistance. Therefore, co...

    Authors: Andrea Halaburková, Rastislav Jendželovský, Ján Kovaľ, Zdenko Herceg, Peter Fedoročko and Akram Ghantous

    Citation: Clinical Epigenetics 2017 9:62

    Content type: Research

    Published on: